72
Participants
Start Date
May 20, 2015
Primary Completion Date
September 30, 2022
Study Completion Date
November 24, 2022
Lisavanbulin Phase 1 dose escalation portion
Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 35 mg/day
Lisavanbulin Phase 2a expansion portion
Recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
UZ Leuven, Leuven
Inselspital Universitätsspital Bern, Bern
Universitätsspital Basel, Basel
Universitätsspital Zürich, Zurich
Kantonsspital St. Gallen, Sankt Gallen
Klinikum der Goethe-Universität Frankfurt, Frankfurt
Universitätsklinikum Heidelberg, Heidelberg
Universitätsklinikum Tübingen, Tübingen
Universitätsklinikum Regensburg, Regensburg
Beatson West of Scotland Cancer Centre, Glasgow
University College London NHS Foundation Trust, London
Sir Bobby Robson Cancer Trials Research Centre; Northern Centre for Cancer Care, Newcastle upon Tyne
Royal Marsden Hospital, Sutton
Lead Sponsor
Basilea Pharmaceutica
INDUSTRY